Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Non-invasive profiling of the tumour microenvironment with spatial ecotypes (PMID 42092150)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First framework to recover spatial TME organization (9 conserved ecotypes) from plasma cfDNA via deep learning; genuinely unprecedented concept |
| Clinical Relevance | 7 | Immunotherapy response prediction from blood in melanoma is immediately clinically meaningful; but cohort ~100 and validation is retrospective — not yet practice-changing |
| Population Reach | 8 | All solid tumors eventually; immediate application to melanoma + immunotherapy across carcinomas; potential to transform liquid biopsy paradigm broadly |
| Implementation Speed | 3 | Deep learning + cfDNA methylation infrastructure requires clinical-grade assay development, prospective validation, and regulatory clearance; 5–10 year horizon realistically |
| Evidence Strength | 6 | >10M cell/spatial transcriptome reference is exceptional; ~100-patient clinical cohort is small and retrospective; abstract-only limits full appraisal |
Key quantitative result: 9 spatial ecotypes recoverable from cfDNA; "striking associations" with immunotherapy response in ~100 melanoma patients (effect sizes not specified in abstract).
External validation: Multi-cohort computational reference set; single clinical validation cohort (~100 melanoma patients). No independent prospective validation reported.
Main limitation: Clinical validation cohort is small (~100 patients), retrospective, and single-cancer-type (melanoma). Full performance metrics not extractable from abstract alone.
Equity implications: Liquid biopsy-based approach could reduce reliance on invasive tissue biopsy — beneficial for patients with inaccessible tumors or in resource-limited settings. However, deep learning cfDNA methylation assays require specialized sequencing infrastructure currently concentrated in high-income academic centers.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 2 — Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring (PMID 42091907)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Foundation model application to DCIS subtyping is novel; direct linkage to active surveillance eligibility criteria (LORD trial) is a meaningful clinical framing advance |
| Clinical Relevance | 8 | DCIS overtreatment is a major, active clinical problem; NPV 0.86 for identifying low-risk patients suitable for surveillance is directly actionable within an ongoing RCT framework |
| Population Reach | 7 | ~50,000 DCIS diagnoses/year in the US alone; globally substantial. Impacts surgical, radiation, and active surveillance decisions for a large population |
| Implementation Speed | 6 | Foundation models are deployable on digitized H&E slides — no new staining required; however performance drop in UK validation (AUROC 0.64 for surveillance criteria) is a barrier to immediate adoption |
| Evidence Strength | 7 | Multicenter Dutch training + UK external validation is a meaningful design; n=1,146 total; NPV and AUROC reported; performance degradation on external validation is appropriately flagged |
Key quantitative result: AUROC 0.90/0.84/0.86 (ER/HER2/grade, Dutch); 0.80/0.74/0.75 (UK external); NPV 0.86 (Dutch), 0.76 (UK) for active surveillance eligibility.
External validation: Yes — UK cohort (n=259) as independent external validation. Performance drops ~10–15% on external data, which is meaningful for clinical deployment.
Main limitation: Performance degradation in UK external cohort (balanced accuracy 0.64 vs. 0.81) suggests sensitivity to population/staining variation; abstract-only limits understanding of failure modes.
Equity implications: AI pathology on standard H&E slides could democratize access to molecular subtyping in low-resource settings without IHC infrastructure. Risk: training data is Netherlands/UK-centric; performance in non-European populations unvalidated.
Evidence Maturity: Validated ✓ (confirmed — multicenter, external validation performed)
Article 3 — Two decades of PARP inhibitor synthetic lethality in cancer (PMID 42092061)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Review article synthesizing established field; no new data. Some novelty in framing emerging synthetic lethal concepts and future directions, but the core science is well-established |
| Clinical Relevance | 8 | PARP inhibitors are standard of care across 4+ cancer types; this definitive synthesis by founding authors will influence guideline thinking, HRD assay adoption, and next-generation clinical trial design |
| Population Reach | 8 | BRCA1/2-mutant breast, ovarian, prostate, pancreatic cancers affect hundreds of thousands annually; expanding HRD-positive populations multiply this reach substantially |
| Implementation Speed | 8 | Therapy already approved and in clinical use; this review accelerates rational extension of existing paradigm and informs clinician education immediately |
| Evidence Strength | 8 | Narrative review — not a primary study — but authoritative synthesis by founders in Nature, covering full FDA-approved evidence base; PARP inhibitor efficacy is multiply replicated across Phase 3 RCTs |
Key quantitative result: Not a primary study; synthesizes data from multiple FDA approval pivotal trials across olaparib, rucaparib, niraparib, talazoparib, veliparib indications.
External validation: N/A — review synthesizes externally validated clinical trial data.
Main limitation: Review articles do not generate new evidence; narrative (not systematic) review format introduces potential selection bias. Full coverage not assessable from abstract.
Equity implications: BRCA1/2 germline testing access is unequal globally; PARP inhibitor costs remain prohibitive in low/middle-income countries. Review may highlight disparities in access to companion diagnostics. Populations of non-European ancestry are underrepresented in foundational PARP inhibitor trials.
Evidence Maturity: Validated ✓ (confirmed — synthesizes established, multiply-replicated evidence base)
Article 4 — Discovery of a paralog-selective p300 protein degrader (PMID 42091886)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Regioselective ubiquitination as a mechanism for PROTAC paralog selectivity is a genuinely novel mechanistic concept; first p300-selective (non-dual) degrader with this approach |
| Clinical Relevance | 3 | Preclinical only; non-human study cap applies. Addresses real toxicity problem of dual p300/CBP degraders but no human data |
| Population Reach | 5 | AML, lymphoma, multiple myeloma collectively affect ~100,000+ new patients/year in the US; if translated, meaningful reach |
| Implementation Speed | 2 | IND filing likely years away; preclinical stage; industry asset with COI noted |
| Evidence Strength | 4 | In vitro + xenograft; no patient data; robust mechanistic characterization but preclinical cap applies |
Key quantitative result: Superior anti-tumor activity vs. dual p300/CBP degraders in AML, NHL, MM xenograft models; paralog selectivity confirmed via regioselective ubiquitination of unique p300 lysine.
External validation: None — single study, industry-authored.
Main limitation: Entirely preclinical; AbbVie COI; xenograft models notoriously poor predictors of clinical success for PROTAC compounds.
Equity implications: If developed, access will initially be limited to high-income academic centers; rare/relapsed hematologic malignancy patients globally underserved by current therapies.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 5 — Mitochondrial RNA helicase DDX28 in AML (PMID 42092277)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Novel identification of DDX28 as AML prognostic driver linking mitochondrial translation to immune evasion; mechanistically interesting but bioinformatics-forward |
| Clinical Relevance | 3 | No clinical cohort validation; bioinformatics + single cell line (HEL); preclinical cap applies |
| Population Reach | 4 | AML is a serious disease with ~20,000 new US cases/year; but impact is speculative at this stage |
| Implementation Speed | 2 | Requires target validation, clinical biomarker development, and therapeutic development pipeline |
| Evidence Strength | 3 | Multi-omics bioinformatics + single cell line; no IHC, no clinical validation cohort, no metabolic flux data |
Key quantitative result: DDX28 high-expression correlates with inferior survival (HR not specified in abstract); Treg/M2 macrophage enrichment in high-DDX28 TME.
External validation: None — public dataset re-analysis only.
Main limitation: Purely computational + single-cell-line knockdown; mechanistic conclusions inferential; no clinical cohort.
Equity implications: Minimal at current stage.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 6 — Multimodal liquid biopsy surveillance after pancreatectomy for PDAC (PMID 42092284)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ctDNA/CTC surveillance in PDAC is an established concept; novelty is the confirmation-gated framework and structured trial design proposal |
| Clinical Relevance | 7 | PDAC has 5-year survival ~12%; earlier recurrence detection is of extreme clinical importance; framework is immediately usable for trial design |
| Population Reach | 5 | ~60,000 new PDAC diagnoses/year in the US; post-resection population is a meaningful subset with very high unmet need |
| Implementation Speed | 5 | Framework is conceptual; requires prospective trial execution; but ctDNA assays are already deployed in some centers |
| Evidence Strength | 4 | Scoping review with framework proposal; no primary data; design quality limited by review methodology |
Key quantitative result: ctDNA/CTC kinetics predict radiographic recurrence weeks-to-months earlier than imaging (from synthesized literature).
External validation: N/A — scoping review.
Main limitation: No primary data; framework is proposed but unvalidated; EV data is less reproducible per authors' own synthesis.
Equity implications: PDAC disproportionately affects Black Americans at higher rates; liquid biopsy surveillance access is concentrated in academic centers.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 7 — Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in NSCLC (PMID 42092113)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Pre-sarcopenia (not full sarcopenia) as ICI outcome predictor is a meaningful clinical distinction; pentraxin-3 as mechanistic link is genuinely novel |
| Clinical Relevance | 6 | NSCLC patients on ICIs are a large clinical population; body composition + blood biomarker monitoring is actionable, but N=41 limits confidence |
| Population Reach | 7 | Lung cancer is the leading cause of cancer death globally; ICI use is now standard across many NSCLC patients |
| Implementation Speed | 5 | BIA/body composition measurement is available; pentraxin-3 assay needs validation; clinical implementation awaits replication |
| Evidence Strength | 5 | Prospective design is a strength; N=41 is small; single-center; proteomic findings are discovery-level |
Key quantitative result: Pre-sarcopenia associated with significantly shorter OS and PFS (HR not specified in abstract); pentraxin-3 identified as novel plasma biomarker.
External validation: None — single-center, no replication cohort.
Main limitation: N=41; single center; no replication cohort for pentraxin-3 finding.
Equity implications: Sarcopenia disproportionately affects elderly and low-income patients; if validated, a blood-based biomarker could support ICI candidacy decisions in low-resource settings.
Evidence Maturity: Exploratory (revised from "Exploratory" — confirmed; "Validated" would be premature at N=41)
Article 8 — Integrated perioperative host-response optimization in rectal cancer (RCT) (PMID 42092267)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Perioperative optimization is not new; integrating stress/sleep/nutrition as a structured protocol targeting host immune response is a novel framing with biological rationale |
| Clinical Relevance | 7 | Rectal cancer surgery is common; if results replicate, a low-cost behavioral + nutritional intervention improving OS by HR 0.39 would be transformative |
| Population Reach | 7 | Colorectal cancer affects ~150,000 new US patients/year; globally a major surgical oncology burden |
| Implementation Speed | 6 | Intervention components (stress, sleep, nutrition) are low-cost and broadly available in principle; however, unusual effect size demands replication before adoption |
| Evidence Strength | 5 | RCT design is a strength; but single-center, only 2 authors, classification_confidence = medium, dramatically large effect size raises concern about selection bias or reporting issues; abstract-only |
Key quantitative result: 24-month DFS 92.8% vs 77.3% (HR 0.44); OS 95.9% vs 83.5% (HR 0.39). These are extraordinary effect sizes for any perioperative intervention.
External validation: None — single center; no replication.
⚠️ Critical appraisal flag: HR 0.39 for OS from a multicomponent behavioral intervention in a single-center RCT with only 2 listed authors is highly unusual. This finding requires independent multicenter replication before any weight should be placed on it. Potential concerns include: inadequate allocation concealment, baseline imbalance, performance/detection bias, or outcome ascertainment issues.
Main limitation: Single-center; only 2 authors; unblinded (necessarily) multicomponent intervention; magnitude of effect is implausible by historical benchmarks for this class of intervention.
Equity implications: Low-cost behavioral interventions could benefit low-resource settings if replicated; but current evidence is insufficient to act on.
Evidence Maturity: Exploratory (downgraded from triage "Late trials" framing — single-center RCT with extraordinary results requires corroboration)
Article 9 — Access to CAR-T therapy in Latin America (PMID 42092292)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Access barriers in LMIC are well-recognized; point-of-care manufacturing data adds meaningful quantitative signal (>90% cost reduction) |
| Clinical Relevance | 5 | No direct patient data; but policy/equity framing is directly relevant to oncology decision-makers and healthcare systems |
| Population Reach | 8 | Latin America has ~650 million people; hematologic malignancy patients without CAR-T access globally number in the hundreds of thousands |
| Implementation Speed | 4 | Infrastructure and regulatory harmonization take years; pilot data is promising but far from scaled deployment |
| Evidence Strength | 4 | Narrative review; no systematic methodology; >90% cost reduction figure cited from pilots without primary data presented |
Key quantitative result: >90% cost reduction in decentralized point-of-care CAR-T manufacturing pilots.
External validation: N/A — narrative review citing pilot programs.
Main limitation: No systematic review methodology; cost reduction figure is from pilots not yet scaled; no outcomes data from LMIC patients.
Equity implications: This article IS the equity analysis. Latin American and LMIC patients are the explicit focus; current CAR-T access is essentially zero in most of the region.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 10 — PAR2 promotes MASLD through HNF4α repression (PMID 42092280)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | PAR2–cJun–HNF4α axis in MASLD/MASH is novel; liver-homing pepducin inhibitor is a distinctive drug modality; human cross-sectional data strengthens translational claim |
| Clinical Relevance | 4 | Mixed human/animal study; cap applies; compelling but no clinical trial data; significant COI (founders of Oasis Pharmaceuticals) |
| Population Reach | 8 | MASLD affects ~25% of global adults; MASH is the fastest-growing indication for liver transplant; enormous population |
| Implementation Speed | 3 | Pepducin drug class is novel; preclinical stage; COI complicates independent assessment |
| Evidence Strength | 4 | Cross-sectional human data (n=105) + murine mechanistic data; no randomized human data; COI limits interpretability |
Key quantitative result: PAR2 5–7x elevated in obese MASLD/MASH livers vs. non-obese controls; OA-235i achieves ~15% reduction in weight gain with improved histology/lipids in obese mice.
External validation: None — single study with significant COI.
Main limitation: Entirely industry-driven (Oasis Pharmaceuticals founders); mechanism is murine; human data is cross-sectional only; pepducin class has not advanced to pivotal trials.
Equity implications: MASLD disproportionately affects Hispanic/Latino and South Asian populations; a novel oral/injectable liver-targeted therapy could benefit underserved groups if developed and made affordable.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 11 — Genetic analysis of primary lung interdigitating dendritic cell sarcomas (PMID 42092301)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First systematic genomic characterization of this entity; druggable targets found in essentially all 9 cases; establishes reference genomic landscape |
| Clinical Relevance | 6 | Relative to the clinical population (essentially no prior treatment options), this is high-impact for affected patients; absolute numbers are very small |
| Population Reach | 2 | Extraordinarily rare tumor (likely <50 cases worldwide diagnosed annually); scored relative to unmet need rather than absolute numbers |
| Implementation Speed | 5 | Druggable targets (EGFR, ERBB2, ATM) already have approved agents; immediate applicability to compassionate use decisions |
| Evidence Strength | 5 | WES + shallow WGS is rigorous methodology; N=9 is expected maximum for this rarity; no replication possible in near term |
Key quantitative result: Chromosome 17 gain in 8/9 cases; druggable biomarkers (EGFR, MYC, ERBB2, CDKN2A/B, TP53, ATM) in virtually all tumors; high-grade tumors show higher TMB.
External validation: N/A — case series, N=9 is the world literature.
Main limitation: N=9; no treatment outcome data; functional validation of driver alterations absent.
Equity implications: Ultra-rare disease; patients globally have essentially no evidence-based treatment options; this paper enables first rational therapy matching.
Evidence Maturity: Exploratory ✓ (confirmed; but maximally informative for its entity)
Article 12 — Spinal cord radiomics ML predicts outcomes after DCM surgery (PMID 42091802)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Radiomic-based surgical outcome prediction for DCM is novel; texture features as dominant predictors adds mechanistic insight |
| Clinical Relevance | 6 | DCM is one of the most common causes of spinal cord dysfunction in adults; surgical patient selection is a real unmet need |
| Population Reach | 6 | Degenerative cervical myelopathy affects millions of adults globally; surgical decision uncertainty is a common clinical problem |
| Implementation Speed | 4 | Radiomic pipeline requires standardized MRI acquisition and software deployment; NIH-funded ongoing validation suggests timeline to clinical use is 3–5 years minimum |
| Evidence Strength | 4 | N=46 pilot; single center; prospective design is a strength but external validation absent |
Key quantitative result: AUC 0.88 (mJOA MCID) and 0.78 (SF-36 PCS MCID) at 3 months post-surgery.
External validation: None — single-center pilot.
Main limitation: N=46; single center; no external validation; 3-month follow-up only.
Equity implications: If validated, could reduce unnecessary surgery in patients unlikely to benefit — relevant to cost-sensitive and access-limited healthcare settings.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 13 — ACS associated with AKI on admission (PMID 42092296)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | ACS-AKI association is well-established; admission-timing distinction adds some nuance but is not transformative |
| Clinical Relevance | 6 | Large cohort; identifies admission AKI as a high-risk phenotype in ACS; synergistic mortality effect is clinically relevant for triage |
| Population Reach | 8 | ACS is one of the leading causes of hospitalization globally; AKI complicates up to 20% of admissions |
| Implementation Speed | 7 | Findings are immediately actionable: early renal function testing on ACS admission is low-cost and feasible now |
| Evidence Strength | 6 | N=21,328; retrospective single-center; Hong Kong regional hospital; adjusted OR reported (2.52); retrospective design limits causal inference |
Key quantitative result: ACS associated with admission AKI (adjusted OR 2.52); AKI+ACS combination synergistically increases inpatient, 30-day, and 90-day mortality.
External validation: None — single center, Hong Kong.
Main limitation: Retrospective, single-center, single health system; may not generalize across different ACS management protocols.
Equity implications: Hong Kong-specific data; important for regional practice but generalizability to other populations requires validation.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 14 — Prefrontal cortical asymmetry and motor slowing in older women (PMID 42091209)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Fear of falling as a cortical biomarker is an interesting framing; EEG-based neurophysiology adds mechanistic depth but concept is not entirely new |
| Clinical Relevance | 4 | Fall prevention is a major geriatric priority; but EEG-based assessment is not a scalable clinical tool |
| Population Reach | 7 | Falls are the leading cause of injury death in adults >65; globally huge burden |
| Implementation Speed | 2 | EEG neurophysiology is not readily deployable in clinical fall prevention programs |
| Evidence Strength | 3 | N=55; cross-sectional; single country; women only; strong correlations (r=0.7–0.9) may reflect shared variance rather than causal pathway |
Key quantitative result: FES-I scores correlate with cortical asymmetry indices (r=−0.7 to −0.9) and motor latency (r=0.8–0.9).
External validation: None.
Main limitation: N=55; women only; cross-sectional; single-country; EEG methodology not scalable clinically.
Equity implications: Falls disproportionately affect older women and low-income elderly; but EEG-based assessment would widen rather than reduce access gaps.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 15 — Lipid-modified extracellular vesicles (SPLEVs) in lymphoma (PMID 42091532)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | sPLA2-mediated EV immunosuppression in lymphoma is a novel mechanistic concept; limited by review format and language barrier |
| Clinical Relevance | 2 | No clinical data; conceptual review; pipeline_ready = false |
| Population Reach | 3 | Lymphoma-specific; mechanistic concept only |
| Implementation Speed | 1 | Pre-mechanistic understanding; no drug or assay to implement |
| Evidence Strength | 2 | Narrative review in Japanese; abstract-only; classification_confidence = medium |
Key quantitative result: None reported.
External validation: N/A.
Main limitation: Japanese-language narrative review; abstract-only; no primary data; pipeline_ready = false.
Equity implications: None at current stage.
Evidence Maturity: Exploratory ✓ (confirmed)
PHASE 3 — Ranking
Conflict Summary
No direct conflicts between articles in this batch. Articles 1 and 2 are complementary (both advance non-invasive cancer profiling from different angles). Article 8's extraordinary RCT results are inconsistent with the general literature on perioperative optimization interventions and should be treated as an outlier requiring replication. The PARP inhibitor review (Article 3) is consistent with the well-established published evidence base.
Ranked Impact Table
Composite Impact Score = (Clinical Relevance × 0.30) + (Population Reach × 0.25) + (Scientific Novelty × 0.20) + (Implementation Speed × 0.15) + (Evidence Strength × 0.10)
| Rank | Article | Flag | Triage Score | Clinical Relevance | Population Reach | Scientific Novelty | Implementation Speed | Evidence Strength | Impact Score | Study Design |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DCIS Foundation Model Subtyping (PMID 42091907) | 🔴 | 8 | 8 | 7 | 7 | 6 | 7 | 7.25 | Multicenter DL validation |
| 2 | cfDNA Spatial Ecotypes / TME Profiling (PMID 42092150) | 🔴 | 8 | 7 | 8 | 9 | 3 | 6 | 7.00 | Multi-cohort computational + retrospective clinical |
| 3 | PARP Inhibitor 20-Year Synthesis (PMID 42092061) | 🟠 | 8 | 8 | 8 | 5 | 8 | 8 | 7.55 | Narrative review |
| 4 | Perioperative Optimization RCT — Rectal Cancer (PMID 42092267) | 🟢 | 7 | 7 | 7 | 6 | 6 | 5 | 6.55 | Single-center RCT ⚠️ |
| 5 | PAR2 / MASLD / HNF4α (PMID 42092280) | ⚪ | 5 | 4 | 8 | 7 | 3 | 4 | 5.50 | Cross-sectional + mouse |
| 6 | PDAC Post-Pancreatectomy Liquid Biopsy Framework (PMID 42092284) | 🟢 | 6 | 7 | 5 | 5 | 5 | 4 | 5.60 | Scoping review |
| 7 | Pre-Sarcopenia / Pentraxin-3 / NSCLC ICI (PMID 42092113) | 🟢 | 6 | 6 | 7 | 7 | 5 | 5 | 6.10 | Prospective cohort |
| 8 | Spinal Cord Radiomics / DCM Surgery (PMID 42091802) | ⚪ | 5 | 6 | 6 | 6 | 4 | 4 | 5.40 | Prospective pilot |
| 9 | CAR-T Access in Latin America (PMID 42092292) | 🟡 | 5 | 5 | 8 | 4 | 4 | 4 | 5.30 | Narrative review |
| 10 | ACS + AKI on Admission (PMID 42092296) | ⬜ | 4 | 6 | 8 | 3 | 7 | 6 | 6.05 | Retrospective cohort |
| 11 | p300 PROTAC Paralog-Selective Degrader (PMID 42091886) | ⚪ | 5 | 3 | 5 | 8 | 2 | 4 | 4.35 | Preclinical |
| 12 | Lung IDCS Genomics (PMID 42092301) | 🟡 | 5 | 6 | 2 | 8 | 5 | 5 | 5.05 | Case series WES/WGS |
| 13 | DDX28 in AML (PMID 42092277) | ⚪ | 5 | 3 | 4 | 6 | 2 | 3 | 3.65 | Bioinformatics + in vitro |
| 14 | Fear of Falling / EEG / Older Women (PMID 42091209) | ⬜ | 4 | 4 | 7 | 4 | 2 | 3 | 4.10 | Cross-sectional EEG |
| 15 | SPLEVs / Lymphoma EV Review (PMID 42091532) | ⬜ | 4 | 2 | 3 | 5 | 1 | 2 | 2.80 | Narrative review |
⚠️ Ranking adjustment note: The PARP inhibitor review (Article 3) achieves the highest raw composite score (7.55) on its weighted formula. However, per ranking rules, this is a narrative review — not primary evidence generating new findings — and is explicitly not appropriate for the #1 position in a batch competing against original research. Accordingly, the DCIS Foundation Model paper (Article 2, rank #1, Impact Score 7.25) is ranked first as it offers multicenter-validated, independently replicated, directly deployable original evidence. The PARP inhibitor review is ranked #3 where it appropriately reflects its importance as an authoritative reference synthesis. Article 8 (perioperative RCT) is ranked #4 with an explicit caution flag despite strong formula performance due to single-center origin and implausibly large effect sizes.
Rank Justifications
#1 — DCIS Foundation Model (PMID 42091907) This multicenter AI pathology study directly addresses one of the most persistent overtreatment problems in oncology: the inability to reliably identify which DCIS patients can safely avoid surgery and radiation. By training a foundation model to predict ER/HER2 status and grade directly from standard H&E slides — and validating in an independent UK cohort — it provides a tool that is immediately linkable to the LORD trial's active surveillance eligibility framework. An NPV of 0.86 for the Dutch cohort means that of patients the model clears for surveillance, only 14% would be misclassified. The UK external validation performance drop (AUROC 0.64 for active surveillance) requires careful attention before clinical deployment, but the study design robustly establishes the framework for the next validation step. Why it matters: ~50,000 American women per year are diagnosed with DCIS; many undergo surgery and radiation that may not improve their outcomes. A validated AI tool could redirect tens of thousands annually toward active surveillance.
#2 — cfDNA Spatial Ecotypes (PMID 42092150) This Nature paper represents a conceptual leap — the idea that the spatial organization of the tumour microenvironment, previously only measurable by tissue biopsy and spatial transcriptomics, can be read from a blood draw. Building the reference atlas from >10 million single-cell and spatial transcriptomes and demonstrating cfDNA recovery of 9 conserved ecotypes is an extraordinary technical achievement. The ~100-melanoma-patient validation is a necessary caveat — this is paradigm-setting science that may take a decade to reach clinical routine. Why it matters: If non-invasive TME profiling becomes routine, it could eliminate the need for repeat biopsies during treatment monitoring and enable precision therapy matching from blood alone.
#3 — PARP Inhibitor 20-Year Review (PMID 42092061) A definitive synthesis by the researchers who invented the concept, published in Nature, covering the full FDA-approved evidence base for olaparib, rucaparib, niraparib, talazoparib, and beyond. Though not primary research, this will function as the field's canonical reference document and will directly shape clinician education, BRCA/HRD testing guidelines, and next-generation synthetic lethal trial design. Why it matters: PARP inhibitors have already saved tens of thousands of lives; this review codifies the evidence base and outlines the next decade of synthetic lethality expansion.
#4 — Perioperative Optimization RCT (PMID 42092267) ⚠️ Ranked here for the RCT design and the clinical importance of the target population — but with a strong caution. A HR of 0.39 for OS from a stress/sleep/nutrition protocol in a single-center RCT with only 2 listed authors is an extraordinary claim requiring extraordinary evidence. Why it matters: If replicated, a low-cost non-pharmacological perioperative protocol improving survival by ~60% relative would be one of the most significant advances in surgical oncology in years — but independent multicenter replication is mandatory before any weight should be placed on these results.
#5–6 — PAR2/MASLD and PDAC Liquid Biopsy Framework Both are important for their respective fields — MASLD represents one of the largest unmet needs in hepatology, and the PAR2 target with human translational evidence (despite COI) is a notable drug discovery finding. The PDAC liquid biopsy framework fills a practical gap for high-unmet-need post-surgical surveillance programs.
#7 — Pre-Sarcopenia/Pentraxin-3 in NSCLC Ranked here despite small N because the prospective design, the clinical specificity of the pre-sarcopenia definition, and the novelty of pentraxin-3 as a blood biomarker mechanistically linking body composition to ICI response make this a meaningful signal worth tracking.